eptinezumab
Sign in to saveAlso known as ALD403
Eptinezumab, sold under the brand name Vyepti, is a medication used for the preventive treatment of migraine in adults. It is a monoclonal antibody that targets calcitonin gene-related peptides (CGRP) alpha and beta. It is administered by intravenous infusion.
~3 min read
Article
9 sectionsContents
- Pharmacology
- Mechanism of action
- Pharmacokinetics
- History
- Society and culture
- Legal status
- Names
- References
- External links
Eptinezumab, sold under the brand name Vyepti, is a medication used for the preventive treatment of migraine in adults. It is a monoclonal antibody that targets calcitonin gene-related peptides (CGRP) alpha and beta. It is administered by intravenous infusion.
Eptinezumab was approved for medical use in the United States in February 2020, and in the European Union in January 2022.
Available in 8 languages
via Wikidata sitelinks · CC0
Connections
intravenous infusion and defusion
Entity
calcitonin gene-related peptide
Entity
humanized antibody
Entity
calcitonin gene-related peptide receptor antagonist
Entity
World Health Organization
Entity
bone
Entity
medication
Entity
circulatory system
Entity
public domain
Entity
digital object identifier
Entity
Paracetamol
Concept
chemical formula
Entity
neurology
Entity
migraine
Entity
molar mass
Entity
serotonin
Entity
Q180686
Entity
antigen
Entity
CAS Registry Number
Entity
United States Food and Drug Administration
Entity